Abstract

Tankyrase (TNKS) plays important roles in the malignancy of several cancers such as human lung tumor, breast cancer, and hepatocellular cancer. However, its exact functions and molecular mechanisms in ovarian cancer remain unclear. In this study, we found that TNKS was aberrantly overexpressed in human ovarian cancer tissues and associated with poor patient prognosis. TNKS inhibition or knockdown not only reduced ovarian cancer cell proliferation, colony formation, migration, invasion, and tumorigenic potential in nude mice but also enhanced the drug susceptibility of ovarian cancer cells through arresting cell cycle and inducing apoptosis. These phenotypic changes correlated with downregulation of targets (Cyclin D1, MDR, and MMP-9) of Wnt/β-catenin signaling. Furthermore, downregulation of TNKS suppressed the glucose uptake, lactate excretion, and cellular ATP levels and increased cellular O2 consumption rates. Molecular mechanism studies revealed that TNKS promoted aerobic glycolysis at least in part due to upregulation of pyruvate carboxylase (PC) via activation of Wnt/β-catenin/snail signaling. In agreement with these findings, expression of TNKS is positively associated with snail and PC in clinical ovarian cancer samples. Our findings identified TNKS as an oncogenic regulator of ovarian cancer cells proliferation that promotes aerobic glycolysis via activation of Wnt/β-catenin signaling, indicating that the TNKS might serve as a potential molecular target for clinical therapy of Wnt/β-catenin dependent ovarian cancer.

Highlights

  • Ovarian cancer is the fourth leading cause of gynaecological malignancy around the world, and estimated 239,000 new patients are diagnosed with ovarian cancer each year [1, 2]

  • To investigate the mechanisms underlying the tumorigenic function of TNKS, we examined whether TNKS1 affected aerobic glycolysis, which is one of the hallmarks of cancer

  • We present for the first the role and mechanism of TNKS in the development of ovarian cancer

Read more

Summary

Introduction

Ovarian cancer is the fourth leading cause of gynaecological malignancy around the world, and estimated 239,000 new patients are diagnosed with ovarian cancer each year [1, 2]. About 70% ovarian cancer patients will relapse after chemotherapy due to drug resistance [4]. Wnt signaling is essential during multiple embryonic developmental progresses and its aberrant activation plays a crucial role in the proliferation, differentiation, metastasis, and multidrug resistance of many human cancers, including ovarian cancer [5, 6]. Wnt signaling can be activated after the combination of Wnt ligands to cell surface receptors, leading to the stabilization of β-catenin, which activates the canonical Wnt pathway [7]. It is common that the related genes of Wnt/β-catenin pathway are mutated in ovarian cancer, suggesting that the Wnt/β-catenin pathway plays a significant role in the development of ovarian cancer [8]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call